Occlutech's Atrial Flow Regulator (AFR) Receives U.S. FDA Breakthrough Device Designation for Heart Failure (HF)

SCHAFFHAUSEN, Switzerland, Jan. 19, 2021 -- (Healthcare Sales & Marketing Network) -- Occlutech, a privately-held company, announced today that the U.S Food and Drug Administration (FDA) has granted the Company a Breakthrough Device designation for its fi... Devices, Cardiology, FDA Occlutech, Atrial Flow Regulator, heart failure
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news